


# **Innovation in Clinical Trials**

Director, Product Management Philipp Abegg






# **Agenda**

Clinical Trial Innovation: Digital Integration

Clinical Trial Innovation: Patient Centricity

Clinical Trial Innovation: Innovating for Process Optimization

4 Conclusion





#### Real-time Track & Trace



Simplifying and improving the experience for our customers



#### Integrated digital and physical supply chain:

15 sensor providers 46 transportation carriers

500,000 shipments One platform

#### Centralizing your shipment data to provide the ultimate oversight and insight:



# Medication adherence challenges in clinical trials and associated risks<sup>1</sup>

#### Non-adherence

- Non-starters 4% do not initiate a study drug
- Each study day, 10–12% does not take their medication while still on treatment
- In long-term studies, after one year, almost 40% of trial participants have stopped taking their medication


#### Risks

- "Ignoring non-adherence could lead to underestimated drug efficacy and safety"
- Loss of statistical power of clinical trials caused by nonadherence.





# Patients' awareness of their adherence patterns changes behavior



#### Showing patients their own dosing history is the most effective means to improve adherence


Vrijens B, et. al. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf. 2006 Feb;15(2):115-21.

Demonceau J, et. al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs. 2013 May;73(6):545-62.

## Thermo Fisher SCIENTIFIC

# What is Omni Everywhere?

This is a single program that is **bringing together all of our data-related activities** into a **centralized location** / function to **enhance our overall data quality and governance**.





# Why patient centricity?



#### **Focus on patient centricity**



Only 15% of trials complete on time and as delays cost money this means just 10% of the trials are accomplished on budget.



Patient centricity is key to achieving higher levels of success.



Focusing on the patient and how to make the trial easier and more tailored to their needs can significantly improve patient adherence, outcomes, recruitment and retention.




Whilst embracing digital transformation, patient engagement must be made a priority with the investment of holistic patient support services throughout the clinical trial

Source: Market Scale: 85% of Clinical Drug Trials Face Delays. What's the True Cost?

## Thermo Fisher SCIENTIFIC

# Direct-to-patient services for decentralized trials\*

Streamline your supply chain by combining direct-to-patient and traditional clinical trial services





51+ countries approved by regulatory experts (where permitted by country regulations)

Ability to scale by using a global network of approved suppliers

Total Transportation

Management leverages the best performing courier

Capabilities to support traditional trials, hybrid trials or 100% virtual trials



#### Tamper evident carton | Improved quality and sustainability



Combines protective carton packaging and tamper-evident sealing

#### **Overview**

Our customers are looking for ways to prevent tamper seals from lifting. Leveraging our expertise in packaging design and practical process improvement tools, we've developed a unique carton design tailored to meet market demands.



Patent granted: March 2024



Re-seal panel for expiry updates



**Specially-designed carton**, adaptable to fit most vial sizes



Offered across our packaging network

#### Suitability


Suitable for vial sizes 2R up to 20R with single or booklet labels



- Eliminates the risk of tamper seals lifting
- Environmental benefit—no foam, no glue
- ✓ 1x vial kit carton for ambient down to -80°C

## Thermo Fisher SCIENTIFIC

# 2024 investments in capacity and innovation





~4,800

Colleagues currently invested in serving our customers



1 site

Netherlands C&GT facility opening Q2 '24



~\$70M

2024 overall capital investment



>\$18M

2024 Investment in Clinical Labels capacity



~\$20M

2024 Technology and Innovation investment



>\$320M

Total investment in Clinical Supplies '20 -'24





# Thank you

We supply the hope that changes lives!

